Depression attention deficit

If I m having a bad day I sometimes still write, unless a reaction to a chemical is affecting my brain. When I can t think clearly, I can t write. And sometimes I feel so apathetic that I can t write. But I m thankful that I have the skill. I think education is so important to prevent others from getting this illness. I believe that chronic fatigue syndrome, fibromyalgia, sick building syndrome and similar conditions with other names are all forms of MCS. They ll find that out with more studies. People just don t know what s wrong with them. They think they ve got asthma, depression, attention deficit disorder and a lot of other problems that can be related to chemical exposures. 

Whitmore, Elizabeth A., Susan K. Mikulich, Laetitia L. Thompson, Paula D. Riggs, Greg A. Aarons, and Thomas J. Crowley. 1997. "Influences on Adolescent Substance Dependence Conduct Disorder, Depression, Attention Deficit Hyperactivity Disorder, and Gender." Drug and Alcoltol Dependence47 87-97. 

As mentioned above, impaired monoamine neurotransmission has been implicated in causing depression, attention deficit disorder and narcolepsy. 

Depression, attention deficit disorder and headaches have been attributed to serotonergic imbalances. 

Neuro-psychiatric disorders have become increasingly of interest as they are more diagnosed, rightly or wrongly, such as depression, attention deficit disorder, fibromyalgia, and restless leg syndrome. 

Norepinephrine NE transporter Human cDNA Depression, Alzheimer s disease, epilepsy, anxiety, attention deficit hyperactivity, angina, asthma, cardiac arrhythmia, cardiac hypertrophy, congestive heart failure, myocardial ischemia, hypertension, artherosclerosis, narcolepsy, orthostatic hypotension, prostatic hyperplasia, rhinitis, diabetes, diarrhea, glaucoma, impotence, obesity, opiate withdrawal pain, Raynaud s disease, preterm labor pain Modulation of norepinephrine concentration in the neuronal synaptic clefts, neuroprotection... 

In view of these factors, it has been suggested that a deficiency of omega-3 fatty acid in the diet will decrease the concentration of these fatty acids available for synthesis of the required phospholipids in the body, including the brain. If this was a chronic deficiency it could increase the risk of development of some disorders, including depression, schizophrenia and attention deficit syndrome. There is some evidence that this is the case. 

Methylphenidate is a CNS stimulant similar to amphetamine however, in usual doses it has a more expressed action on mental activity rather than physical or motor activity. In therapeutic doses it does not raise blood pressure, respiratory rate, or increase heart rate. All of these effects as well as a number of others are associated with general excitement of the CNS. Tremor, tachycardia, hyperpyrexia, and a state of confusion can result from using large doses. It is used in treating moderate depression and apathetic conditions, and also as an adjuvant drug for treating attention deficit disorder in children.Synonyms of this dmg are meridil, ritalin, and others. 

The developmental neurotoxicity guideline, accepted by OECD in 2007, has added the important aspect of behavioral effects of pre- and postnatal exposure to chemicals. This development arose from the notion that behavioral disorders in man such as anxiety, depression, phobias, autism, and attention deficit hyperactivity disorder, which appear to show increasing prevalences in western societies, may have a perinatal origin (4, 5). In the absence of causal inferences with respect to chemicals it seems nevertheless prudent to assess in a risk assessment whether such causal relations may exist. 

Uniabeied Uses Treatment of attention-deficit/hyperactivity disorder, brain injury-re-lafed underarousal, depression, endozepine stupor, multiple sclerosis-related fatigue, parkinson-related fatigue, seasonal affective disorder... 

Unlabeled Uses Treatment of Alzheimer s disease, attention-deficit-hyperactivity disorder, depression, early Parkinson s disease, extrapyramidal symptoms, negative symptoms of schizophrenia... 

In early-onset OCD, comorbid psychiatric disorders are present in about 80% of the cases. Major depression is seen in approximately 66% attention-deficit hyperactivity disorder (ADHD), oppositional defiant disorder (ODD), or multiple anxiety disorders in 50% and enuresis or speech and language disorders in 33%... 

Approximately three-quarters of children with OCD have comorbid diagnoses. These include tic disorders (24%-30%) and mood disorders, especially major depression (26%-29%). Riddle and colleagues (1990) found that 38% of children with OCD have other anxiety disorders, while Swedo (1989) more specifically identified increased rates of simple phobias (17%), overanxious disorder (16%), and separation anxiety disorder (7%). Other reported comorbidities include specific developmental disabilities, adjustment disorder with depressed mood, oppositional defiant disorder, attention-deficit hyperactivity disorder (ADHD), conduct disorder, and enuresis/encopresis (Swedo et ah, 1989b Riddle et ah, 1990). 

St. John s wort has been used to treat a wide range of ailments for more than 2000 years, and is said to have been prescribed by Hippocrates himself. Apart from depression, St. John s wort is being promoted or used as a treatment for attention-deficit hyperactivity disorder (ADHD), anxiety, stress, obsessive-compulsive disorder, sleep problems, nocturnal enuresis, bacterial and viral infections such as HIV-AIDS, respiratory conditions, peptic ulceration, inflammatory arthritis, cancer, and skin wounds (Rey and Walter, 1998 Walter et ah, 2000). It is also said to increase libido, an application dating from the Middle Ages (Fletcher, 1996). No empirical evidence is currently available to support any of these uses. 

ADHD, attention-deficit hyperactivity disorder EKG, electrocardiogram GI, gastrointestinal MD, major depression MR, mental retardation OCD, obsessive-compulsive disorder PTSD, post-traumatic stress disorder. Trade names are in parentheses. Doses are general guidelines. All doses must be individualized with appropriate monitoring. Weight-corrected doses are less appropriate for obese children. 

Gammon, G.D. and Brown, T.E. (1993). Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. / Child Adolesc Psychopharmacol 3 1-10. 

Younger children with manic symptoms tend to have severe functional impairment and comorbid psychopathology such as anxiety dysregulation, disruptive behaviors, and developmental delays that further complicate their clinical picture. In addition, these children may have mood symptoms that merge with other disorders, making manic episodes difficult to define. Irritability is part of the clinical picture of depression, anxiety, attention-deficit hyperactivity disorder (ADHD), and oppositional defiant disorder (ODD). Poor concen-... 

A potential limitation of most of the controlled studies discussed above relates to the numerous exclusion criteria used for patient selection. For example, in order to find homogenous samples, major depression, bipolar disorder, Tourette s disorder, psychosis (clomipramine, fluvoxamine and fluoxetine trials), primary psychiatric disorder other than OCD (clomipramine and sertraline trials), and attention deficit/hyperactivity disorder (ADHD), autism, or other developmental disorders (clomipramine and fluoxetine trials) were excluded. Thus it remains unknown how well these controlled studies will generalize to more naturalistic clinical populations that are highly comorbid and where exclusion criteria are not applied. 

Multiple studies have noted the comorbidity between PTSD and depressive disorders (Goenjian et ah, 1995), as well as between PTSD and externalizing disorders (Cuffe et ah, 1994 Glod and Teicher, 1996). Younger children with PTSD may present with classical features of attention-deficit hyperactivity disorder (ADHD), including hyperactivity, impulsivity, restlessness, irritability, and distractibility (Cuffe et ah, 1994 De Beilis and Putnam, 1994 McLeer et ah, 1994 Loof et al., 1995 De Beilis et ah, 1999). More serious externalizing disorders, such as conduct disorder (CD) and oppositional defiant disorder (ODD), are also commonly comorbid with PTSD (Arroyo and Eth, 1985 Steiner et al., 1997). Similarly, the relationship between PTSD and substance use disorders in children has been noted in several studies (Arroyo and Eth, 1985 Brent et al., 1995 Loof et al., 1995). 

Daviss, W., Bentivoglio, P., Racusin, R., Brown, K., Bostic, J., and Wiley, L. (2001) Buproprion sustained release in adoelcents with comorbid attention-deficit hyperactiivty disorder and depression. Am Acad Child Adolesc Psychiatry 40 307—314. 

Note Doses are provided as general guidelines only, and are not meant to be definitive. All doses must be individualized and monitored through appropriate clinical and/or laboratory means. ADHD, attention-deficit hyperactivity disorder bid, twice daily c, capsule CYP, cytochrome P450 EKG electrocardiogram FDA, Food and Drug Administration IM, intramuscular MDD, major depressive disorder OCD, obsessive-compulsive disorder PDD, pervasive developmental disorder qd, once daily qhs each bedtime qoWk, every other week t, tablet tid, three times daily TS, Tourette s syndrome WBC, white blood cell count. 

Mood disorders are frequently associated with cognitive impairment. In younger depressives attention and concentration are primarily affected, and responses in speed-related tasks may be abnormally slowed. Complaints about serious cognitive dysfunction, which are particularly frequent in older patients with depression, cannot always be fully substantiated by means of objective tests (O Hara et al., 1986). Nevertheless, significant deficits in the following areas have been found ... 

Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991 148 564-577. 

Cala S, Crismon ML, Baumgartner J. A survey of herbal use in children with attention-deficit-hyperactivity disorder or depression. Pharmacotherapy 2003 23(2) 222-230. 

---